Soluble RAGE and the RAGE Ligands HMGB1 and S100A12 in Critical Illness: Impact of Glycemic Control with Insulin and Relation with Clinical Outcome
暂无分享,去创建一个
[1] Chin-Chou Wang,et al. Impact of Serum Biomarkers and Clinical Factors on Intensive Care Unit Mortality and 6-Month Outcome in Relatively Healthy Patients with Severe Pneumonia and Acute Respiratory Distress Syndrome , 2014, Disease markers.
[2] R. Ramasamy,et al. Unlocking the biology of RAGE in diabetic microvascular complications , 2014, Trends in Endocrinology & Metabolism.
[3] A. Fabio,et al. Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis , 2013, Scandinavian journal of clinical and laboratory investigation.
[4] M. Boermeester,et al. S100A12 and Soluble Receptor for Advanced Glycation End Products Levels During Human Severe Sepsis , 2013, Shock.
[5] Y. Mori,et al. Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan , 2013, BMC Nephrology.
[6] T. Zima,et al. Receptor for advanced glycation end products (RAGE) and glyoxalase I gene polymorphisms in pathological pregnancy. , 2012, Clinical biochemistry.
[7] L. Moldawer,et al. Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care , 2012, The journal of trauma and acute care surgery.
[8] R. Ramasamy,et al. Receptor for Advanced Glycation End Products (RAGE) and Implications for the Pathophysiology of Heart Failure , 2012, Current Heart Failure Reports.
[9] Y. Arabi,et al. sRAGE in diabetic and non-diabetic critically ill patients: effects of intensive insulin therapy , 2011, Critical care.
[10] Tsukasa Nakamura,et al. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. , 2011, Clinical biochemistry.
[11] Y. Mori,et al. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[12] F. Chiarelli,et al. What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children? , 2011, Antioxidants & redox signaling.
[13] N. A. Sadik,et al. The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis , 2011, Molecular and Cellular Biochemistry.
[14] M. Cohen,et al. Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans. , 2010, The Journal of trauma.
[15] S. Kennedy,et al. RAGE, vascular tone and vascular disease. , 2009, Pharmacology & therapeutics.
[16] A. Sauaia,et al. HMGB1 IS MARKEDLY ELEVATED WITHIN 6 HOURS OF MECHANICAL TRAUMA IN HUMANS , 2009, Shock.
[17] O. O. Gul,et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. , 2009, Clinical biochemistry.
[18] G. Van den Berghe,et al. Tissue-specific glucose toxicity induces mitochondrial damage in a burn injury model of critical illness , 2009, Critical care medicine.
[19] F. Santilli,et al. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. , 2009, Current medicinal chemistry.
[20] P. Saftig,et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] Y. S. Kim,et al. The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. , 2008, Transplantation proceedings.
[22] Y. Tomino,et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. , 2008, Diabetes research and clinical practice.
[23] A. Carter,et al. Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[24] E. Ruokonen,et al. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis , 2008, Intensive Care Medicine.
[25] P. Nawroth,et al. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis , 2008, Critical care.
[26] D. Stern,et al. Soluble forms of RAGE: an index of vascular stress? A commentary on "Soluble RAGE in type 2 diabetes: association with oxidative stress". , 2007, Free radical biology & medicine.
[27] D. Foell,et al. S100 proteins expressed in phagocytes: a novel group of damage‐associated molecular pattern molecules , 2007, Journal of leukocyte biology.
[28] U. Klotz,et al. Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease , 2006, Journal of Clinical Pathology.
[29] D. Stern,et al. Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.
[30] Ilse Vanhorebeek,et al. Intensive insulin therapy protects the endothelium of critically ill patients. , 2005, The Journal of clinical investigation.
[31] M. Bianchi,et al. HMGB1: guiding immunity from within. , 2005, Trends in immunology.
[32] B. Bistrian,et al. Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.
[33] M. Brownlee. Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.
[34] K. Tracey,et al. HMGB1 as a late mediator of lethal systemic inflammation. , 2001, American journal of respiratory and critical care medicine.
[35] M Schetz,et al. Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.
[36] K. Tracey,et al. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock , 1999, The Lancet.